On March 29, the CLHIA submitted its views to the Government of Canada on its consultation on a national strategy for high-cost drugs for rare diseases. The submission provides comments on how to address key issues in the government’s discussion paper, including improving patient access, evidence-based decision making and sustainability for an effective rare disease strategy. It also presents risk and cost sharing approaches that include private payers. These approaches will minimize impacts to patients and ensure the sustainability of the program over time.